Fulcrum Therapeutics Reports $19.6 Million Net Loss in Q3 2025, Sees Decrease in Operating Expenses

Fulcrum Therapeutics, Inc. reported a net loss of $19.6 million for the third quarter of 2025, a slight improvement compared to a net loss of $21.7 million in the same period last year. For the nine months ending September 30, 2025, the company experienced a significant net loss of $54.5 million, contrasting sharply with a net income of $6.8 million for the same period in 2024, primarily due to the absence of collaboration revenue following the termination of its agreement with Sanofi. The company recognized no collaboration revenue during the current quarter, down from $80 million in the previous year, which was attributed to an upfront payment from Sanofi for the licensing of losmapimod.

Operating expenses for the third quarter of 2025 totaled $21.9 million, a decrease from $25.1 million in the prior year. This reduction was driven by lower research and development costs, which fell to $14.3 million from $14.6 million, and a decrease in general and administrative expenses, which dropped to $7.6 million from $8.4 million. The company also reported no restructuring expenses in the current quarter, compared to $2.1 million in the same quarter of 2024. The decrease in operating expenses reflects the company's strategic decision to reprioritize its research and development activities and reduce its workforce.

As of September 30, 2025, Fulcrum Therapeutics had total assets of $214.9 million, down from $260.7 million at the end of 2024. The decline in assets was primarily due to a decrease in cash and cash equivalents, which fell to $47.1 million from $58.2 million, and a reduction in marketable securities from $182.8 million to $153.6 million. The company's accumulated deficit increased to $573.9 million, reflecting ongoing operational losses. The company’s total liabilities remained relatively stable at $16.5 million, compared to $17.7 million at the end of 2024.

In terms of operational developments, Fulcrum Therapeutics continues to advance its clinical-stage product candidate, pociredir, for the treatment of sickle cell disease. The company has completed enrollment in the 20 mg dose cohort of its Phase 1b trial and plans to provide clinical data by the end of 2025. Additionally, the company is pursuing the development of other drug candidates for genetically defined rare diseases, including bone marrow failure syndromes. Fulcrum anticipates that its expenses will continue to rise as it progresses through clinical trials and seeks regulatory approvals for its product candidates.

Looking ahead, Fulcrum Therapeutics expects to finance its operations through a combination of equity offerings, debt financings, and collaborations. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses into 2028, although it acknowledges the potential for earlier depletion of resources. The company remains focused on advancing its research and development efforts while navigating the challenges inherent in the biotechnology industry.